Advanced in Transient Ischemic Attack (TIA)

Christopher F. Bladin

Melbourne, VIC, AU 
Advanced in Transient Ischemic Attack (TIA)
Melbourne, VIC, AU 
OverviewLocationsClinical Research

Overview

Christopher Bladin practices in Melbourne, Australia. Mr. Bladin is rated as an Advanced expert by MediFind in the treatment of Transient Ischemic Attack (TIA). His top areas of expertise are Stroke, Transient Ischemic Attack (TIA), Low Blood Sugar, and Thrombectomy.

His clinical research consists of co-authoring 88 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 12 articles in the study of Transient Ischemic Attack (TIA).

Gender
Male

Locations

Melbourne, VIC, Australia
Other Locations
Parkville, NSW, Australia
VIC, Australia
Parkville, VIC, Australia
Heidelberg, VIC, Australia
Box Hill, VIC, Australia
Doncaster, VIC, Australia
Blackburn, VIC, Australia
St. Albans, Box Hill, Royal North Shore Hospital And Kolling Institute, St. Vincent's Hospital Sydney, Gold Coast, QLD, Australia
St. Albans, Royal North Shore Hospital And Kolling Institute, Royal North Shore Hospital, St. Leonards, Sydney, NSW, Australia
Clayton, VIC, Australia
Clayton, QLD, Australia
Newcastle, NSW, Australia
Monash, SA, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Multicentre, Randomised Controlled Trial of Exenatide Versus Standard Care in Acute Ischemic Stroke (TEXAIS)
A Multicentre, Randomised Controlled Trial of Exenatide Versus Standard Care in Acute Ischemic Stroke (TEXAIS)
Enrollment Status: Unknown
Publish Date: September 14, 2021
Intervention Type: Drug
Study Drug: Exenatide
Study Phase: Phase 2
STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial.
STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial.
Enrollment Status: Completed
Publish Date: February 26, 2020
Intervention Type: Drug
Study Phase: Phase 2
Extending the Time for Thrombolysis in Emergency Neurological Deficits
Extending the Time for Thrombolysis in Emergency Neurological Deficits
Enrollment Status: Completed
Publish Date: August 31, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

88 Total Publications

Framingham Risk Score Prediction at 12 Months in the STANDFIRM Randomized Control Trial.
Framingham Risk Score Prediction at 12 Months in the STANDFIRM Randomized Control Trial.
Journal: Journal of the American Heart Association
Published: April 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bladin's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile